Eran Rotem: And regarding your second question, so as you know, RK, we are not allowed to disclose the phase of AbbVie with the dermal filler products. They are our partners, and we are respecting their requests. What we are allowed to say, and say that, and it’s very important, is that we are expecting to achieve the milestone with AbbVie — the AbbVie program, the dermal filler, this year. And this is super important, and this is what we are allowed to say now.
Swayampakula Ramakanth: Okay, thanks for that. And then on the breast implant program, what’s the next steps you would be doing?
Yehiel Tal: So as I indicated earlier in my talk, the next step would be to launch a large animal trial with clinically relevant size implants which are going to be like 100 cc in size. So, this will be during this year, 2023.
Swayampakula Ramakanth: And so, this is a study that you are conducting on your dollar. And do you have an idea of how long it would take for you to get the data that you need to take it to the clinic?
Yehiel Tal: Well, first of all, the study — a preclinical study with follow-ups takes about one year. And then you have all the (ph) analysis for the 12-months endpoint. And then it depends on the results. And we will, of course, need to get this point of time to decide whether another animal study would be required as a pivotal study towards submission to the regulatory authorities or maybe this study would be sufficient; it’s too early to say at this point of time.
Swayampakula Ramakanth: Okay. And then regarding the breast implant program, I am assuming you are looking for a collaborator. Can you comment anything on that progress?
Yehiel Tal: Regarding collaborator, we’re continuously looking for collaborations. And at this point of time, of course, we cannot elaborate on our discussions. And you know the situation with respect to collaboration.
Swayampakula Ramakanth: Great, thank you very much. Thanks for taking all my questions.
Yehiel Tal: Thank you, RK.
Operator: Thank you. I believe that is our last question from our live audience participant. So, I’ll now turn the call back over to Mr. Eran Rotem to read any written questions that came in from the audience in advance or during this call.
Eran Rotem: Thank you. So, the first question is as follows, would the patient require any allergy testing prior to receiving a plant-based collagen filler?
Yehiel Tal: So, allergy testing prior to receiving a plant-based collagen filler is not required at all. This test was required in past when filler made of tissue-extracted collagen were used. And our plant-derived collagen does not elicit immune response or allergies since it is pure and does not carry residues like growth factors from the host tissue. So, the answer is a allergy test prior to receiving the plant-derived collagen filler is not required.
Eran Rotem: Okay, the next question is the following. What are production cost differences between animal-extracted tissue and the process of producing your collagen in tobacco plants? Are these easy to procure?
Yehiel Tal: So, the CollPlant production process is very efficient. And we believe that in commercial scale, the cost is going to be competitive with the cost of tissue-extracted collagen.
Eran Rotem: Okay, so the last question that is see here is regarding rhCollagen production capacity. So, what we can say about that?
Yehiel Tal: So, our production capacity is scalable. And we believe that we can satisfy the upcoming commercial demand for our products or our partners’ products in the coming years.
Operator: Okay, so that concludes our great questions from the audience. And I’ll now pass it back to Yehiel Tal, CollPlant’s Chief Executive Officer for any closing remarks, Yehiel?